Clinical interventions in aging · 2026
Efficacy of First-Line EGFR-TKI Treatment in Octogenarians with Lung Adenocarcinoma and Common EGFR Mutations.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Chi-Wei, Hsiao Hsiu-Yi, Lin Yu-Ching, Fang Yu-Hung, Fang Tien-Pei, Lin Chin-Kuo, Lung Jrhau, Hung Ming-Szu
Аннотация
OBJECTIVE: This retrospective cohort study compared the efficacy and tolerability of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) between octogenarians (aged ≥80 years) and non-octogenarians with advanced EGFR-mutated lung adenocarcinoma.
METHODS: We retrospectively analyzed 151 patients with advanced lung adenocarcinoma harboring common EGFR exon 19 deletions or exon 21 L858R mutations who received first-line EGFR-TKI therapy. Patient characteristics, treatment outcomes, and adverse events were evaluated.
RESULTS: Progression-free survival (PFS) did not differ significantly between octogenarians and non-octogenarians. Overall survival (OS) was shorter in octogenarians, which may be partly explained by lower rates of subsequent therapy and age-related clinical factors. No significant differences in treatment-related toxicities were observed between the two groups.
CONCLUSION: This study provides clinically relevant real-world evidence supporting the feasibility of first-line EGFR-TKI therapy in octogenarians with EGFR-mutated lung adenocarcinoma. Chronological age alone should not preclude carefully selected very elderly patients from receiving EGFR-TKI treatment.
METHODS: We retrospectively analyzed 151 patients with advanced lung adenocarcinoma harboring common EGFR exon 19 deletions or exon 21 L858R mutations who received first-line EGFR-TKI therapy. Patient characteristics, treatment outcomes, and adverse events were evaluated.
RESULTS: Progression-free survival (PFS) did not differ significantly between octogenarians and non-octogenarians. Overall survival (OS) was shorter in octogenarians, which may be partly explained by lower rates of subsequent therapy and age-related clinical factors. No significant differences in treatment-related toxicities were observed between the two groups.
CONCLUSION: This study provides clinically relevant real-world evidence supporting the feasibility of first-line EGFR-TKI therapy in octogenarians with EGFR-mutated lung adenocarcinoma. Chronological age alone should not preclude carefully selected very elderly patients from receiving EGFR-TKI treatment.